Q32 Bio Inc. (NASDAQ: QTTB) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $95.00 price target on the stock.
Q32 Bio Inc. (QTTB)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
QTTB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QTTB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QTTB alerts
High impacting Q32 Bio Inc. news events
Weekly update
A roundup of the hottest topics
QTTB
News
- Q32 Bio Inc. (NASDAQ: QTTB) is now covered by analysts at Raymond James. They set a "strong-buy" rating and a $90.00 price target on the stock.MarketBeat
- Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024 [Yahoo! Finance]Yahoo! Finance
- Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024PR Newswire
- Q32 Bio to Participate in Upcoming September Investor ConferencesPR Newswire
- Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097 [Seeking Alpha]Seeking Alpha
QTTB
Earnings
- 8/8/24 - Miss
QTTB
Sec Filings
- 10/25/24 - Form SC
- 10/16/24 - Form 4
- 10/10/24 - Form 4
- QTTB's page on the SEC website